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Background. Dolutegravir (DTG) is an integrase strand-transfer inhibitor (INSTI) used for treatment of human immunodeficiency 
virus (HIV)–infected individuals. Owing to its high genetic barrier to resistance, DTG has been clinically investigated as maintenance 
monotherapy to maintain viral suppression and to reduce complication and healthcare costs. Our study aims to explain the underlying 
mechanism related to the emergence of a S230R substitution in patients who experienced virologic failure while using DTG monotherapy.
Methods. We evaluated the effect of the S230R substitution in regard to integrase enzyme activity, viral infectivity, replicative 
capacity, and susceptibility to different INSTIs by biochemical and cell-based assays.
Results. The S230R substitution conferred a 63% reduction in enzyme efficiency. S230R virus was 1.29-fold less infectious than 
wild-type virus but could replicate in PM1 cells without significant delay. Resistance levels against DTG, cabotegravir, raltegravir, 
and elvitegravir in tissue culture were 3.85-, 3.72-, 1.52-, and 1.21-fold, respectively, in virus with the S230R substitution.
Conclusions. Our data indicate that the S230R substitution is comparable to the previously reported R263K substitution in some 
respects. Virologic failure during DTG monotherapy can occur through the development of the S230R or R263K mutation, without 
the need for high-level DTG resistance.
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Human immunodeficiency virus type 1 (HIV-1) integrase is 
an enzyme that plays a critical role in the HIV-1 replication 
cycle by catalyzing the stable insertion of proviral DNA into the 
host genome in a 2-stage reaction process: 3ʹ processing and 
strand-transfer [1]. The new class of integrase strand-trans-
fer inhibitors (INSTIs) inhibits the latter activity of HIV 
integrase and includes 3 clinically approved INSTIs to date: ral-
tegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG) [2]. 
Additionally, 2 investigational INSTIs, cabotegravir (CAB) and 
bictegravir, are currently undergoing clinical trials [3, 4].
DTG is effective in treating both treatment-naive and treat-
ment-experienced HIV-positive individuals. DTG-based 
regimens showed statistically noninferior or superior virologic 
suppression rates when compared to combined first-line anti-
retroviral therapies containing RAL, efavirenz, or darunavir/
ritonavir [5–7]. Unlike the 2 other approved INSTIs, DTG seems 
to possess a high genetic barrier to resistance, and it can be 
active against HIV isolates harboring certain major single RAL-
associated and EVG-associated resistance mutations [8–10]. 
However, the preexistence of multiple major and minor RAL/
EVG resistance mutations that predate DTG initiation, most 
notably changes in the Q148 or N155 resistance pathways, are 
associated with a higher rate of virologic failure with the latter 
drug [9]. As a consequence, when alternative treatment is not 
possible, DTG is commonly recommended as a 50-mg dose 
twice daily for individuals living with viruses that harbor INSTI 
resistance mutations [9]. In treatment-experienced, INSTI-naive 
individuals who used DTG as part of partly active combined anti-
retroviral therapy regimens in the SAILING clinical trial, DTG 
could select for the R263K integrase substitution [11]. In cell cul-
ture, R263K was also selected under DTG pressure, and this sub-
stitution was associated with low levels of resistance, decreased 
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replicative capacity, and progressive decline in integration [12, 
13]. In RAL or EVG resistance pathways, additional minor 
mutations often accumulate after primary resistance mutations, 
which further increase resistance levels and/or compensate for 
the reduction in replication imparted by primary mutations. By 
contrast, instead of restoring viral replication, R263K secondary 
substitutions—H51Y, M50I, and E138K—further decrease both 
replicative capacity and levels of integration, while increasing 
only modestly levels of resistance against DTG [14–16].
When used as part of a fully functional combination antiret-
roviral therapy regimen, DTG is robust against the emergence of 
resistance. In fact, only 1 patient with virologic failure involving 
a de novo resistance mutation has been described so far in this 
clinical setting: a treatment-naive patient who initiated treat-
ment with a combination of DTG, abacavir, and lamivudine but 
was unable to adhere to treatment and eventually experienced 
treatment failure after 11.6 months with the development of a 
T66I substitution [17]. Somewhat surprisingly, 3.4% of treat-
ment-naive participants (2 of 58) experienced treatment failure 
together with the development of resistance mutations in this 
study, the second case being linked to a M184V substitution in 
reverse transcriptase [17]. DTG-based dual therapy has proven 
to maintain HIV-1 suppression in a high proportion (>90%) of 
patients, even in highly treatment-experienced individuals with 
some cases of drug resistance development [3, 18–21]. During 
the past 2 years, clinical studies of the safety and efficacy of DTG 
as maintenance monotherapy have been conducted [3, 19–22]. In 
this clinical setting, individuals have experienced virologic fail-
ure with the development of resistance substitutions at various 
positions in the gene encoding integrase, including Q148H/R, 
N155H, or G118R [23, 24]. Results from the Dolutegravir as 
Maintenance Monotherapy for HIV (DOMONO) study [25], 
which was conducted to investigate the efficacy of DTG mono-
therapy as a switch maintenance option for HIV-infected 
patients with virologic suppression, are included in the compan-
ion article by Wijting et al [26] in this issue, which reports the 
characterization of viral isolates from patients who experienced 
virologic failure, including 3 in whom INSTI resistance–associ-
ated mutations developed at positions R263K, N155H, or S230R.
To date, the S230R substitution has not been exhaustively 
characterized in regard to viral replication and INSTI suscep-
tibility. Similar to R263K, S230R is found within the integrase 
C-terminal domain, a region that exhibits high conformational 
flexibility during DNA binding [27]. This missense nonpoly-
morphic mutation was previously observed accompanying 
other primary mutations in tissue culture selection experiments 
with EVG or RAL, but it has little effect on HIV susceptibility to 
both drugs when tested as a primary single mutation [28, 29]. It 
may act in combination with other substitutions by moderately 
decreasing susceptibility to RAL and EVG [28]. The S230R sub-
stitution was also observed together with the A49G and R263K 
mutations in 1 participant with virologic failure in the SAILING 
trial [30]. Results from in vitro tissue culture selection experi-
ments with DTG also showed infrequent and transient emer-
gence of this substitution [31].
In our study, to understand the role of the S230R substitution 
in virologic failure among patients using DTG monotherapy, 
we characterized S230R in regard to integrase enzymatic activ-
ity, viral fitness, and resistance against INSTIs, using biochem-
ical and cell-based assays. We found that S230R caused a >50% 
reduction of overall integrase activity but had minimal (<20%) 
impact on viral infectivity and replicative capacity. Phenotypic 
resistance analysis showed a 2–4-fold decrease in the half-maxi-
mal inhibitory concentration (IC50) of DTG. Our results suggest 
that mutations conferring low levels of drug resistance against 
DTG can be detected after virologic failure in very specific clin-
ical circumstances, such as monotherapy or functional mono-
therapy. Whether such mutations are clinically relevant when 
DTG is used as part of a 3-drug fully active combination antire-
troviral therapy regimen remains to be fully understood.
MATERIALS AND METHODS
Cells and Reagents
PM1, HEK 293T, and TZM-bl reporter cells were obtained from 
the National Institutes of Health (NIH) AIDS Reagent Program, 
National Institute of Allergy and Infectious Diseases, NIH, from 
Dr Marvin Reitz [32] (for PM1 cells), Dr Andrew Rice [33] (for 
HEK 293T cells), and Dr John C. Kappes, Dr Xiaoyun Wu and 
Tranzyme (for TZM-bl cells) [34–36]. Cell culture protocols 
were described previously [37]. RAL, EVG, DTG, and CAB 
were provided by Merck, Gilead Sciences, and GSK.
Expression and Purification of Recombinant Integrases
The pET-15b plasmid coding for subtype B integrase containing 
the S230R mutation (pET-15B-INS230R) was generated by site- 
directed mutagenesis, using pET-15b-INWT as a template and 
the following primers: S230R: 5ʹ-TTTCCAAACTGGATCTCT 
CCTGTCCCTGTAATAAACC-3ʹ (sense) and 5ʹ-GGTTTAT-
TACAGGGACAGGAGAGATCCAGTTTGGAAA-3ʹ (anti-
sense) [14]. Selected clones were sent for DNA sequencing to 
confirm the presence of the desired mutation. The protocol for 
expression and purification of His-tagged HIV-1 integrases, 
using the nickel–nitrilotriacetic acid affinity chromatogra-
phy matrix (Qiagen) under native conditions, was previously 
described [12].
Cell-Free Strand Transfer Assay
Integrase strand-transfer activities of wild-type integrase 
(INWT) and integrase with the S230R mutation (INS230R) were 
executed by measuring time-resolved fluorescence, based 
on a protocol previously established in our laboratory [15]. 
A nonlinear regression Michaelis-Menten model within the 
GraphPad Prism 5.0 software was used to determine maximal 
strand-transfer activity (Vmax) and half of the concentration of 
DNA necessary to reach Vmax (Km).
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Susceptibility of Purified Integrases to Antiviral Compounds
Strand-transfer experiments were performed in the presence of 
0–1000 nM DTG, RAL, EVG, or CAB. A total of 25 μL of drug 
was added before adding 25 μL of target DNA duplexes to the 
96-well plates, followed by incubation for 1 hour at 37°C. To 
calculate the inhibitor constant of each drug, Ki, which is the 
concentration required to yield 50% maximal inhibitory activ-
ity, all values were fit to sigmoid dose-response curve by using 
GraphPad Prism 5.0 software.
Viruses
The pNL4-3IN(S230R) infectious molecular clone containing 
S230R was produced by site-directed mutagenesis, using pNL4.3 
as template [12]. The pNL4-3 plasmid was obtained through the 
NIH AIDS Reagent Program, from Dr Malcolm Martin [38]. 
The primer set used for mutagenesis was as described above, 
and the presence of mutations was confirmed by sequencing. 
WT and S230R homogenous viruses were produced by trans-
fection, using 293T cells as previously described [37]. A reverse 
transcriptase assay was performed for quantification of viruses, 
as previously described [39]. Briefly, 10 μL of culture fluid was 
added to 0.5 U/mL of poly(rA)/p(dT)12–18 template/primer, 
50  mM Tris-HCl, pH 7.8; 75  mM KCl; 5  mM dithiothreitol; 
5 mM MgCl2; 0.05% Triton X-100; 2% ethylene glycol; 0.3 mM 
reduced glutathione; and 5 μCi of [3H]dTTP (70–80 Ci/mmol; 
2.5 mCi/mL). Reverse transcription was allowed to occur at 
37°C for 4 hours, followed by precipitation of products with 
200 μL of 10% trichloroacetic acid and 20 mM sodium pyro-
phosphate for 30 minutes on ice. Radioactive precipitates were 
filtered through Millipore 96-well MultiScreen HTS FC filter 
plates, washed twice with 200  μL of 10% trichloroacetic acid 
and 150 μL of 95% ethanol, and quantified by liquid scintilla-
tion spectrometry, using a Perkin-Elmer 1450 MicroBetaTriLux 
microplate scintillation and luminescence counter.
Infectivity in TZM-bl Cells
Relative infectivity of the NL4-3IN(S230R) or NL4-3IN(WT) viruses 
was measured using a noncompetitive short-term infectiv-
ity assay in 30 000 TZM-bl cells, as previously described [15]. 
Resulting luciferase activities were normalized relative to 
reverse transcriptase levels. Levels of viral infectivity were rep-
resented as the relative 50% effective concentration (EC50). The 
EC50 is the amount of virus needed to stimulate TZM-bl cells to 
produce half of the maximal luciferase activity. The results were 
analyzed by GraphPad Prism 5.0 software, using a log(agonist) 
versus response-variable slope model to determine EC50 values.
Drug Susceptibility Assays
In vitro drug susceptibility assays were performed by infection 
of 30 000 TZM-bl cells with a volume of NL4-3IN(WT) or NL4-
3IN(S230R) viruses equivalent to a reverse transcription activity 
of 67 500 units. Cells were plated with serial dilutions from 0 
to 10 µM of RAL, EVG, DTG, or CAB 24 hours before infection. 
Luciferase levels were measured 48 hours after infection, using 
a protocol similar to that of the infectivity assay, except that 
IC50 values were determined using a log(inhibitor) versus 
response-variable slope model in GraphPad Prism 5.0.
Replication Capacity in PM1 Cells
To monitor replicative capacity in tissue culture, 30 000 PM1 
cells were infected with 67 500 reverse transcriptase units of 
either NL4-3IN(WT) or NL4-3IN(S230R) viruses in 96-well plates for 
1 hours at 37°C, washed to remove unbound viruses, and then 
plated in Roswell Park Memorial Institute medium. At days 3, 
6, 9, 13, 17, and 21 after infection, cell-free medium containing 
viruses was withdrawn to measure reverse transcriptase activity. 
At each time point, 100 μL of fresh medium containing 10 000 
uninfected PM1 cells was added to the culture to allow new 
rounds of viral infection to occur.
Statistical Analysis
Each experiment was performed independently at least 2 times, 
with experiments performed in triplicate each time, except 
when mentioned otherwise. Strand-transfer activities, relative 
infectivity indexes, and fold changes in EC50 and IC50 were 
normalized to WT values. Results are expressed as means ± 
standard errors of the mean (SEM) [28]. Student t tests were 
performed to measure the statistical significance of differences 
between data sets, defined as a P value of < .05. Analyses were 
performed using the OpenEpi Toolkit (available at: http://www.
openepi.com).
RESULTS
S230R Substitution Decreases Integrase Strand-Transfer Activity
First, to determine the optimal concentration of enzymes for the 
strand-transfer assay, we used various concentrations of purified 
recombinant INWT and INS230R, ranging from 0 to 1600 nM, in 
the presence of a fixed amount of target DNA (20 nM). Figure 1A 
shows that maximal activities were achieved at 400 nM for both 
INWT (mean activity [±SEM], 4022 ± 448.9 relative fluorescence 
units [RFU]/hour) and INS230R (915.17 ± 105.6 RFU/hour). The 
enzymatic activity of INWT was 2–6-fold higher than that of 
INS230R at all protein concentrations tested (P = .0005 at 400 nM 
integrase, by the Student t test; n = 6). At 12.5 nM, the lowest 
protein concentration, the strand-transfer activity of INWT was 
2-fold higher than that of INS230R, and this ratio reached 4.4– 
6.2-fold for higher protein concentrations (Figure  1A). 
Increasing the concentration of purified integrases from 
400 nM to 800 nM resulted in an approximately 50% reduction 
in catalytic activity for both enzymes.
To compare the overall enzyme efficiency of INWT and 
INS230R, we performed strand-transfer assays in the presence 
of various concentrations of target DNA, ranging from 0 to 
128  nM. Maximal activity saturation curves were generated 
for both enzymes, from which the maximal strand-transfer 
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activity of INS230R was calculated (Figure  1B). The calculated 
mean Vmax (±SEM) was 25 917  ±  782.5 RFU/hours for INWT 
as compared to 21 287 ± 851 RFU/hours for INS230R (Figure 1C 
and Table 1), which means that the reaction rate of INS230R was 
about 18% lower than that of INWT (P  =  .001 by the Student 
t test; n  =  9). The mean Km (±SEM) was 8.9  ±  0.95  nM for 
INWT and 19.9 ± 2.30 nM for INS230R (P = .001 by the Student 
t test; n = 9), which was calculated by fitting the curve for each 
enzyme (Figure 1D and Table 1). This suggests that INS230R has 
an approximately 2.3-fold lower affinity than the WT enzyme 
for the DNA target. We also evaluated the overall enzyme 
performance by calculating the Vmax/Km ratios of INWT and 
INS230R, which reflect both binding and catalytic activities. We 
observed that S230R caused a 63% reduction in the overall cata-
lytic strand-transfer efficiency of integrase (Table 1).
Effects of the S230R Substitution on Susceptibility of Purified Integrases 
to DTG, RAL, EVG, and CAB
To evaluate the impact of S230R on phenotypic resistance of 
purified integrases to RAL, EVG, DTG, and CAB, we performed 
strand-transfer assays of purified INWT and INS230R in the pres-
ence of increasing drug concentrations (range, 0–1000  nM). 
Table 1. Comparison of Strand-Transfer Activity of Purified Recombinant Wild-Type and S230R Integrase
Recombinant Enzyme Vmax, RFU/h, Mean (95% CI) P
a Km, nM, Mean (95% CI) Fold Change P
a Vmax/Km Fold Change
Wild type 25 917 (24 341–27 494) 8.9 (6.97–10.80) 1 2918 1
S230R 21 287 (19 572–23 001) .001 19.9 (15.26–24.55) 2.26 .001 1070 0.37
Each experiment was repeated 3 times in triplicate for each integrase concentration.
Abbreviations: CI, confidence interval; Km, half of the concentration of DNA necessary to reach Vmax; RFU, relative fluorescence units; Vmax, maximal strand-transfer activity.
aCompared to wild-type enzyme, by the Student t test (OpenEpi Toolkit). Values < .05 are considered statistically significant.
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Figure 1. Mean strand-transfer activities (±standard errors of the mean) of purified recombinant wild-type integrase (WT) and integrase bearing the S230R substitution 
(S230R). *P < .05 compared to WT, by the Student t test (OpenEpi Toolkit). A, Strand-transfer activity in the presence of 20 nM target DNA and increasing concentrations of 
purified integrases. For each protein concentration, assays were performed twice independently, in triplicate, yielding 6 independent values. B, Strand-transfer activity in the 
presence of 400 nM purified WT or S230R integrase and increasing concentrations of target DNA. For each protein, assays were performed 3 times independently, in tripli-
cates, yielding 9 independent values for each target DNA concentration and protein. C, Calculated maximum strand-transfer activities (Vmax) for WT and S23OR integrases, 
using protein concentrations specified in panel B. D, Half of the concentration of DNA necessary to reach Vmax (Km) for purified WT and S23OR integrases, using values from 
panel B.
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Inhibition constants (Ki values), indicators of each inhibitor’s 
potency, were determined from the dose-response curves 
(Table 2). DTG inhibited INWT and INS230R, with Ki values of 
1.27  nM and 3.33  nM, respectively, representing a 2.62-fold 
decrease in DTG susceptibility for INS230R (Table  2). S230R 
also exhibited low levels of resistance against CAB (1.92-fold), 
RAL (2.16-fold), and EVG (3.19-fold; P values are presented in 
Table 2).
The S230R Substitution Slightly Decreases Viral Infectiousness
Given the clinical relevance of the S230R substitution, we also 
examined its effect on viral infectivity. In cell-based assays, the 
NL4.3IN(S230R) virus manifested a 1.29-fold impairment in viral 
infectivity, with an EC50 of 613 834 reverse transcriptase units, 
compared with WT virus, which displayed an EC50 of 473 473 
reverse transcriptase units (Figure  2A). Differences in EC50 
between NL4.3IN(WT) and NL4.3IN(S230R) were statistically signif-
icant (P = .016 by the Student t test).
Replication Kinetics of NL4.3IN(S230R) Resistant Virus in PM1 Cells
To confirm whether S230R causes a replicative defect, we eval-
uated the ability of the NL4.3IN(S230R) virus to replicate in PM1 
cells over a 21-day period, compared with the NL4.3IN(WT) virus 
(Figure  2B). At day 3 after infection, we obtained detectable 
and comparable reverse transcriptase activities from the culture 
fluids of cells infected by either WT or S230R mutant viruses, 
suggesting that the replication of S230R virus was not delayed 
as compared to that of WT virus. The reverse transcriptase lev-
els continued to increase and reached their peaks at day 9 after 
infection for both viruses (Figure  2B). At both 6 and 9  days 
after infection, the average reverse transcriptase activities were 
14% higher for the WT virus than for the S230R virus (P = .029 
and P = .025, respectively, by the Student t test), suggesting that 
S230R decreases HIV-1 replicative capacity by 14%. At other 
time points, we observed nearly identical reverse transcriptase 
levels for WT and S230R viruses (Figure 2B).
Phenotypic Susceptibility of NL4.3IN(S230R) Virus Against DTG, CAB, EVG, 
and RAL in Tissue Culture
To confirm results of cell-free analysis of the effects of S230R 
on resistance to RAL, EVG, DTG, and CAB, we conducted 
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Figure 2. A, Mean relative viral infectivity (±standard error of the mean [SEM]) in 
TZM-bl cells of wild-type (WT) and S230R viruses, measured by luciferase fluores-
cence, 48 hours after infection. Values were calculated from 3 independent experi-
ments, each performed in triplicate, yielding 9 values per point. B, Viral replication 
kinetics over a 21-day period in PM1 cells. PM1 cells were infected with the same 
amount of reverse transcriptase (RT) for all viral stocks. Levels of RT in cell-free cul-
ture fluids were monitored by quantitative RT assays. Means (±SEMs) of 3 different 
experiments, each performed in triplicate, for each virus are presented. EC50, 50% 
effective concentration; RLU, relative luminescence units; RTU, reverse transcrip-
tase units. aCompared to wild-type genotype, by the Student t test (OpenEpi Toolkit). 
A value < .05 is considered statistically significant.
Table 2. In Vitro Susceptibilities of Purified Recombinant Integrase to Dolutegravir (DTG), Cabotegravir (CAB), Raltegravir (RAL), and Elvitegravir (EVG) 
in Biochemical Assays
Recombinant 
Enzyme
DTG CAB RAL EVG
Ki, nM, Mean ± 
SEM
Relative 
Fold 
Change Pa
Ki, nM, Mean ± 
SEM
Relative 
Fold 
Change Pa
Ki, nM, Mean ± 
SEM
Relative 
Fold 
Change P a
Ki, nM, Mean ± 
SEM
Relative 
Fold 
Change Pa
Wild type 1.27 ± 0.13 1 1.76 ± 0.41 1 6.40 ± 0.5 1 2.30 ± 0.13 1
S230R 3.33 ± 0.22 2.62 .004 3.38 ± 0.55 1.92 .08 13.8 ± 5.5 2.16 .3 7.34 ± 0.47 3.19 .009
Each experiment was repeated 3 times in triplicate for each drug concentration.
Abbreviations: Ki, inhibitor constant; SEM, standard error of the mean.
aCompared to wild-type enzyme, by the Student t test (OpenEpi Toolkit). Values < .05 are considered statistically significant.
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phenotypic resistance assays by using TZM-bl cells. HIV-1 
susceptibility to the inhibitory effects of INSTIs was mea-
sured using the IC50, which is the concentration of inhibitor 
required to reduce infection by half. As shown in Figure  3, 
S230R increased IC50 values of both DTG and CAB. Compared 
with the IC50 of WT virus and in agreement with data from 
strand-transfer assays in the presence of INSTIs, S230R caused 
a 3.8-fold decrease in susceptibility to DTG and CAB (Table 3). 
For RAL and EVG, S230R virus displayed 1.52-fold and 1.21-
fold reductions in susceptibility, respectively, relative to WT 
virus (Table 3 and Figure 3). In sum, S230R conferred higher 
levels of resistance against DTG and CAB than against RAL 
and EVG.
DISCUSSION
Originally, S230R was described as a secondary resistance 
mutation selected in vitro with diketo acid L-708 906, one of the 
first INSTIs to be developed [29]. Later, this substitution was 
observed as a S230R/S mixture combined with one or more of 
the major resistance substitutions at positions Q148R, E92Q, 
and/or T66I under EVG drug pressure [28]. In the phase 2 
and 3 clinical trials that led to the regulatory approval of RAL, 
S230R was found to be associated with Y143 substitutions, 
preferentially Y143C, in patients who experienced virologic 
failure [40, 41]. The companion article in this issue, describing 
the results from the DOMONO study, reports the emergence of 
S230R in isolation in 2 patients who experienced virologic fail-
ure during DTG monotherapy [26]. The first patient had plasma 
HIV-1 RNA levels of 1570 copies/mL and had experienced viro-
logic suppression during efavirenz/tenofovir disoproxil fuma-
rate/emtricitabine treatment for 25  months before switching 
to DTG 50 mg once daily. The second patient had experienced 
virologic suppression during DTG/ABC/3TC treatment for 
8  months before switching to DTG monotherapy. Viral loads 
in this patient remained <20 copies/mL until week 29, when 
they increased to 700 copies/mL and S230R was detected in the 
integrase sequence. Anecdotally, S230R was detected in viruses 
isolated from one humanized mouse that did not achieve dura-
ble suppression of HIV viremia after 4 months of DTG mono-
therapy [42]. It should be noted that S230N but not S230R is 
a natural polymorphism that has been observed in drug-naive 
patients [43]. Together, these data suggest that S230R is a genu-
ine DTG resistance substitution. Accordingly, we characterized 
its effects in regard to integrase activity, viral replication, and 
susceptibility to INSTIs, to further appreciate its clinical impli-
cations for DTG therapy.
120
100
80
60
40
20
0
–8 –6 –4
Log(DTG), nM
–2 0 2
120
100
80
60
40
20
0
–8 –4
Log(CAB), nM
–2 0 2
DTG CAB
WT
S230R120
100
80
60
40
20
0
–6 –4
Log(RAL), nM
–2 0 42
RAL
R
el
at
iv
e 
R
L
U
120
100
80
60
40
20
0
–6 –4
Log(EVG), nM
–2 0 42
EVG
Figure 3. Dose-response infectivity curves in the presence of dolutegravir (DTG), cabotegravir (CAB), raltegravir (RAL), and elvitegravir (EVG) for wild-type (WT) and S230R 
viruses. Data reflect viral resistance to RAL, EVG, DTG, and CAB in TZM-bl cells. TZM-bl cells were infected with NL4.3IN(WT) or NL4.3IN(S230R) virus over 48 hours, and luciferase 
levels were measured. Infectivity of NL4.3IN(WT) virus is shown for comparison. Dose-response curves were produced from the compilation of 3 independent experiments, each 
performed in triplicate. Error bars indicate means (±standard errors of the mean). RLU, relative luminescence units.
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Our strand-transfer assays showed only a modest (18%) 
reduction in maximum strand-transfer activity with the INS230R 
enzyme compared to INWT (Figure 1C and Table 1). This is con-
sistent with results of a previous study, which also did not show 
any significant reduction in strand-transfer activity for INS230R 
[29]. In addition, we found that S230R was associated with a 
2.3-fold decrease in integrase binding affinity for target DNA. 
The Vmax/Km value revealed that S230R impaired the overall 
integrase performance to 63% of that of WT integrase (Table 1). 
This reduction is comparable to levels previously reported 
for R263K [12]. Most substitutions associated with resistance 
against INSTIs are mapped to the catalytic core domain of 
integrase, with only 2 residues (R263K and S230R/N) among 
38 substitutions residing within the C-terminal domain. It has 
been reported that the C-terminal domain is important for inte-
grase multimerization, interaction with host factors, and viral 
DNA binding. For both WT and S230R proteins, concentrations 
>400 nM resulted in an approximately 50% decrease in catalytic 
activity (Figure 1A), likely because of the formation of high-or-
der inactive integrase multimers. Cross-linking studies demon-
strated that the interaction between the integrase C-terminal 
domain and viral DNA involves residues 230, 246, 262, 263, and 
264 [44–46]. Elsewhere, X-ray crystallography and cryoelectron 
microscopy revealed that R263 and surrounding residues par-
ticipate in integrase interaction with viral DNA [47, 48]. Based 
on these structural models, in the context of active integrase 
tetramers, R263K may cause changes to the conformation of the 
catalytic site, through multiple relevant hydrogen bond inter-
actions between amino acids, that explain its reported negative 
effect on integrase–viral DNA binding affinity [12]. It should 
also be noted that both S230 and R263 residues are located on 
flexible loops and turns lying at the surface of proteins that are 
often involved in different biochemical interactions [27]. It is 
thus possible that the S230R substitution behaves in a similar 
manner as R263K to impair strand transfer.
When S230R is present as an individual mutation, previous 
reports indicated that it did not cause a large reduction in EVG 
or RAL susceptibility in vitro [27–29]. Using both biochemical 
and cell culture assays, we confirmed these results in this study. 
In addition, we demonstrated that, in cell-free assays, both CAB 
and DTG may still remain active against the INS230R mutant, 
with <3-fold increases in Ki values for these drugs, compared 
with INWT. Similarly, S230R conferred an approximately 4-fold 
increase in resistance against DTG or CAB in cell culture. Our 
viral infectivity replication assays showed that the infectious-
ness of S230R-containing virus was  1.3-fold lower  than that 
of the WT virus and that its replication kinetics were almost 
identical to those of WT. Only a minimal (14%) reduction in 
peak viral replication was observed, compared with WT. This 
contrasts with results from biochemical assays that showed that 
INS230R displayed a substantial (63%) loss of enzyme activity rel-
ative to INWT. In this regard, long terminal repeat–binding and 
3ʹ-processing assays may further clarify the effect of S230R on 
integrase activities.
The same reasons may help explain the differences between 
resistance levels measured with purified recombinant enzymes 
(Table  2) and those obtained with viruses (Table  3). Notably, 
IC50 values are dynamic measures, whereas Ki values are con-
stant values. Regarding viral fitness and INSTI susceptibility, 
R263K resulted in a 1.7-fold decrease in viral infectiousness and 
an approximately 3–4-fold increase in DTG IC50 values [12, 49]. 
Given its relative benign effect on fitness, the rare occurrence 
of the S230R substitution in the clinic or during in vitro selec-
tion may be because it typically requires a G-to-C transversion, 
rather than an easier G-to-A transition as for R263K [31, 50]. 
N155H was another substitution described to have a signif-
icant negative impact on strand-transfer activity (fold change 
in Km of 2.72 as compared to WT) and viral infectivity and to 
confer minor changes in IC50 of DTG in vitro, but the effects 
were sufficient to cause virologic failure in one patient during 
DTG monotherapy [49]. The current study demonstrates that 
the S230R substitution caused similar effects on strand-trans-
fer activity, viral replicative capacity, and phenotypic resistance 
against DTG.
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Table 3. Viral Susceptibilities of Wild-Type and S230R Viruses to Dolutegravir (DTG), Cabotegravir (CAB), Raltegravir (RAL), and Elvitegravir (EVG) in 
Cell-Based Assays
Virus
DTG CAB RAL EVG
Relative IC50, nM, 
Mean  
(95% CI)
Fold  
Change Pa
Relative IC50, nM, 
Mean  
(95% CI)
Fold  
Change P a
Relative IC50, nM,  
Mean (95% CI)
Fold  
Change Pa
Relative IC50, nM, 
Mean (95% CI)
Fold  
Change Pa
Wild type 2 (1.63–2.45) 1 0.22 (.18–.27) 1 9.33 (8.71–9.99) 1 0.84 (.60–1.18) 1
S230R 7.69 (6.74–8.8) 3.85 .02 0.82 (.68–1) 3.72 .019 14.18 (13.24–16.68) 1.52 .013 1.02 (.66–1.59) 1.21 .57
Each experiment was repeated 3 times in triplicate for each drug concentration.
Abbreviations: CI, confidence interval; IC50, half-maximal inhibitory concentration.
aCompared to wild-type virus, by the Student t test (OpenEpi Toolkit). Values < .05 are considered statistically significant.
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